INVESTORS
A leading antibody innovation powerhouse
We are a fast-growing, international biotech company committed to improving the lives of people with our differentiated antibody medicines.
We have committed to a new vision for our future that by 2030, our knock-your-socks-off “KYSO” antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases.
| ||||||||
| ||||||||
Investor Relations Overview
Creating value by turning science into medicine
Our ambition is to develop drug candidates that have the potential to transform cancer treatment. We do so by leveraging the success of our partnered assets and continuing to invest in our novel proprietary pipeline and technology platforms.
Founded in Copenhagen, Denmark in 1999, Genmab A/S’s ordinary shares are listed on the Nasdaq Copenhagen A/S under the ticker symbol GMAB and are traded as part of the OMXC25. Genmab’s American Depositary Shares issued under the ADR Program are listed in the U.S. on the Nasdaq Global Select Market under the ticker symbol GMAB, and the shares are included in the NASDAQ Biotechnology Index (Nasdaq: NBI).
Genmab’s First Nine Months 2022 Financial Results
On November 9, Genmab announced its financial results for the first nine months of 2022.View Report | Download Presentation | Watch On-Demand Webcast
Latest news
Events and presentations
Financial Reports
Search and read Genmab’s most recent and previous financial reports.
SEC Filings
See our statements, reports, and other forms submitted to the U.S. Securities and Exchange Commission (SEC).
Corporate Social Responsibility
We are committed to being a sustainable and socially responsible biotech company.
Our Science
Our passion for innovation is driven by data and rooted in science.
The Pipeline
See the results of our innovation that is driven by data.
Governance Overview
Our commitment to corporate governance is based on ethics and integrity.
ELECTRONIC SHAREHOLDER COMMUNICATIONS
Register your email to receive electronic shareholder communications from Genmab including the calling of Genmab’s Annual General Meeting. Log on to the InvestorPortal, add your email under “My profile” and select your communication preferences.
Investor inquiries
Our aim is to deliver reliable and transparent information to our shareholders. If you have questions about Genmab, our products or other relevant shareholder information, please use the information below to contact us. We will handle your personal data in accordance with our Privacy Policy.
Andrew Carlsen
Vice President,
Head of Investor RelationsTelephone: +45 3377 9558
Email: [email protected]
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
For general Investor Relations Inquiries please contact [email protected].
Examine key figures
See snapshots of our balance sheets,
cash flow and other statementsVisit the investor library
Access our financial reports, webcasts, presentations and more
Stay informed
Sign up to receive email alerts with
our latest news